Article
Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
International journal of hematology - 1 Aug 2022
Edahiro Yoko, Ohishi Kohshi, Gotoh Akihiko, Takenaka Katsuto, Shibayama Hirohiko, Shimizu Takayuki, Usuki Kensuke, Shimoda Kazuya, Ito Masafumi, VanWart Scott A, Zagrijtschuk Oleh, Qin Albert, Kawase Hiroaki, Miyachi Narihisa, Sato Toshiaki, Komatsu Norio, Kirito Keita
Abstract excerpt
Ropeginterferon alfa-2b is a novel, site-selective, monopegylated recombinant human interferon alfa-2b. Safety and efficacy of ropeginterferon alfa-2b for the treatment of polycythemia vera were demonstrated in clinical studies conducted in European countries, but clinical studies in Japanese patients are lacking. This phase 2, open-label, multicenter, single-arm study investigated the safety and efficacy of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.